secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2025-10-08T23:59:59+00:00
Accession:  0001453687-25-000104
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Cartesian Therapeutics appoints June Seymour as Chief Accounting Officer effective Oct 27, 2025
--------------------------------------------------------------------------------

- Annual base salary of $385,000; eligible for annual performance bonus targeted at 35% of base salary.
- Receives $80,000 sign-on bonus and option to purchase 50,000 shares vesting over four years.
- Ms. Seymour most recently served as SVP, Finance and Accounting at DNAnexus; previously VP Finance at Neogene Therapeutics.
- CFO Blaine Davis continues as both principal financial officer and principal accounting officer.
- Employment agreement includes six-month severance (base salary and pro-rata bonus) and 12-month non-compete.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368725000104/0001453687-25-000104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368725000104/rnac-20251002.htm
  HTML page:      https://secwatch.observer/filing/0001453687-25-000104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer